18 and older, any sex, with Colorectal Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Likelihood of Any Colorectal Cancer (CRC) Screening (for Study-eligible Patients)Primary· Primary outcome at 6 months following CCO eligible patient list pull date,
Adjusted 6-month any CRC screening for enrollees in clinic units. These values are predicted estimates rather than crude number \[%\] generated using marginal standardization and accounting for clustering and covariates (i.e., sex, age, and Medicaid health plan). Claims and vendor data were used to determine whether or not the patient completed CRC screening (i.e., fecal testing, FIT-DNA, sigmoidoscopy, CT colonography, or colonoscopy). To assess effectiveness of CRC screening completion, we used the generalized form of hierarchical linear model (binomial distribution with logit link) to accou
Group
Value
95% CI
SMARTER CRC Intervention Year 1
11.8
10 – 13.5
SMARTER CRC Usual Care
4.5
3.6 – 5.4
Completion of CRC ScreeningSecondary· Up to 12 months
Completed CRC screening at 12 months. Claims and vendor data were used to determine whether or not the patient completed CRC screening (i.e., fecal testing, FIT-DNA, sigmoidoscopy, CT colonography, or colonoscopy).
Group
Value
95% CI
SMARTER CRC Intervention Year 1
16.8
15.3 – 18.2
SMARTER CRC Usual Care
9
8.0 – 10.0
Rate of CRC Screening Among the Intervention-eligible PopulationSecondary· 6 months
In the intervention clinics only, the list of patients eligible for screening was scrubbed by clinics. This percent is the N completed CRC screening out of the N included in intervention outreach after clinics scrubbed the list of eligible patients.
Group
Value
95% CI
SMARTER CRC Intervention Year 1
181
Time to Screening From Study-eligible Patient List PullSecondary· Up to 12 months
Days from study-eligible patient list pull to abnormal FIT result. Number of days at individual level.
Group
Value
95% CI
SMARTER CRC Intervention Year 1
118.5
± 293.9
SMARTER CRC Usual Care
103.2
± 383.2
Abnormal FIT ResultsSecondary· 6 months
Number of participants with abnormal FIT Results
Group
Value
95% CI
SMARTER CRC Intervention Year 1
19
Usual Care
7
Patient Navigation Trainings (Intervention Group)Secondary· Up to 12 months
Clinic participation (i.e., attendance) in patient navigation training, Year 1 clinical trial
Group
Value
95% CI
SMARTER CRC Intervention Year 1
22
Patient Navigation Completed (Intervention Group)Secondary· Up to 12 months
Patient navigation implemented = one or more live phone contact with the patient (binary at the individual level).
Group
Value
95% CI
SMARTER CRC Intervention Year 1
22
Follow-up Colonoscopy CompletionSecondary· Up to 12 months
The percentage of patients with abnormal FIT who completed follow-up colonoscopy within 12 months
Group
Value
95% CI
SMARTER CRC Intervention Year 1
49.1
SMARTER CRC Usual Care
19.7
Time to Colonoscopy From Abnormal FIT ResultSecondary· Up to 12 months
Days from abnormal FIT result to completion of follow-up colonoscopy. Number of days at the individual level.
Group
Value
95% CI
SMARTER CRC Intervention Year 1
96.3
72.6 – 119.9
SMARTER CRC Usual Care
114.6
50.0 – 179.2
Adenomas or Cancers DetectedSecondary· Up to 12 months
Whether or not eligible patient had an adenoma or cancer detected. Binary at individual level.
Adenomas
Group
Value
95% CI
SMARTER CRC Intervention Year 1
7
Usual Care
14
Cancers
Group
Value
95% CI
SMARTER CRC Intervention Year 1
1
Usual Care
4
Key Implementation BarriersSecondary· Up to 36 months
Qualitative key informant interviews with clinic and payer stakeholders to identify implementation barriers.
COVID disruptions
Group
Value
95% CI
SMARTER CRC Intervention and Usual Care Year 1
4
Staffing Disruptions
Group
Value
95% CI
SMARTER CRC Intervention and Usual Care Year 1
19
Mailing Delays
Group
Value
95% CI
SMARTER CRC Intervention and Usual Care Year 1
5
Did Not Mention
Group
Value
95% CI
SMARTER CRC Intervention and Usual Care Year 1
54
Sponsor's own description
This study collects information to provide a model for how to rapidly adapt and scale-up multilevel interventions through clinic-health plan partnerships to reduce the burden of colorectal cancer (CRC) on the United states population. This study may improve colorectal cancer screening rates, follow-up colonoscopy, and referral to care in rural Medicaid patients.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT05291988 — A Multilevel Approach for Improvement in Screening of Colorectal Cancer in Rural Communities, The Screen to Save Trial
· NA
· terminated
NCT05447923 — Addressing Disparities in Colorectal Cancer Screening in Black and Underserved Phoenix Communities
· NA
· recruiting
NCT05200611 — Fecal Immunochemical Test for Advanced Adenoma Detection in Colorectal Cancer Screening
· unknown
NCT05810714 — Audio and Video Brochures for Increasing Colorectal Cancer Screening Among Adults Living in Appalachia
· NA
· completed
NCT06090643 — Implementation Research to Increase Colorectal Cancer Screening Rates Among Low Income and Ethnic Minority Groups
· NA
· active not recruiting
Other recruiting trials for Colorectal Carcinoma
Currently open trials in the same condition.
NCT07405476 — Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative I
· Phase 2
· recruiting
NCT06557733 — An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis
· Phase 2
· recruiting
NCT07291414 — A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients
· NA
· recruiting
NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr
· Phase 2
· recruiting
NCT07192068 — Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration
· Phase 2
· recruiting
Other OHSU Knight Cancer Institute trials
Trials by the same sponsor.
NCT05453851 — A Surgical Procedure (Total Pancreatectomy) With a Transplant Procedure (Islet Cell Autotransplantation) for the Treatme
· Phase 1, PHASE2
· not yet recruiting
NCT07511504 — Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanc
· Phase 2
· not yet recruiting
NCT07434128 — Mammogram Pretreatment With Ulipristal Acetate
· Phase 2
· not yet recruiting
NCT07504835 — GET FIT Together: Testing a Socially Enhanced Exercise Program in Older Men With Prostate Cancer
· NA
· not yet recruiting
NCT07498517 — Safety and Efficacy of a Single Dose of Gruticibart to Prevent CRT
· Phase 2
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by OHSU Knight Cancer Institute
Last refreshed: 19 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04890054.